Department of Cardiology, Amphia Hospital, Breda, the Netherlands
Department of Cardiology, Oosterschelde Hospitals, Goes, the Netherlands
Department of Cardiology, Medical Spectrum Twente, Enschede, the Netherlands
Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands
Department of Cardiology , Medical Center Leeuwarden South, Leeuwarden, the Netherlands
Department of Cardiology, Atrium Medical Centre, Heerlen, the Netherlands
H.T. Jørstad Department of Cardiology F3-241, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, the Netherlands
Background. Patients with coronary artery disease are at high risk of coronary events and death, but effective secondary prevention can reduce this risk. There is a gap between guidelines on secondary prevention and the implementation of these measures, which could potentially be reduced by nurse led prevention clinics (NLPC).
Objectives. The aim of the current study is to quantify the impact of NLPC on the risk of cardiovascular events in patients with established coronary artery disease.
Methods. A randomised, multicentre clinical trial of NLPC in addition to usual care or usual care alone in post-acute coronary syndrome patients. (Neth Heart J 2009;17:322–8.)
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Allen JK. Cholesterol management: an opportunity for nurse case managers. J Cardiovasc Nurs 2000; 14: 50–8.
Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363–72.
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. EurHeart J. 2003; 24): 1601–10.
Burgers JS, Simoons ML, Hoes AW, Stehouwer CD, Stalman WA. Guideline ‘Cardiovascular Risk Management. Ned Tijdschr Geneeskd. 2007; 151: 1068–74.
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547–59.
Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review. Circulation. 2005; 112: 924–34.
Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002; 162: 2197–202.
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282: 2340–6.
Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730–7.
Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003; 115: 473–9.
Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002; 360: 2–3.
EuroAspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001; 22: 554–72.
Wood D. EuroAspire III, Euro Heart Survey on Preventive Cardiology study. Eur Soc Cardiol, Oral Presentation 2007.
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001; 357: 995–1001.
Clark AM, Hartling L, Vandermeer B, McAlister FA. Metaanalysis: secondary prevention programmes for patients with coronary artery disease. Ann Intern Med. 2005; 143: 659–72.
Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ. 2003; 326: 84.
Wiggers LC, Smets EM, Oort FJ, Storm-Versloot MN, Vermeulen H, van Loenen LB, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med. 2006; 13: 79–88.
Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol. 2001; 54: 217–24.
Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk. 2001; 8: 291–7.
Sprangers RLH, Stam F, Smid HEC, Stehouwer CDA, Hellemans IM. Multidisciplinary structured lifestyle intervention reduces the estimated risk of cardiovascular morbidity and mortality. Neth Heart J. 2004; 12: 443–9.
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA. 2004; 291: 2727–33.
Rutten G, De Grauw WJC, Nijpels G, Goudswaards AN, Uitewaal PJM, Van der Does FEE, et al. NHG-Standaard Diabetes Mellitus type 2. HuisartsWet. 2006; 49: 137–52.
RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists
Study design, objectives and expected results
H. T. Jørstad
A. M. W. Alings
A. H. Liem
C. von Birgelen
J. G. P. Tijssen
C. J. de Vries
D. J. A. Lok
J. A. Kragten
R. J. G. Peters
- Bohn Stafleu van Loghum
Neu im Fachgebiet Kardiologie
Mail Icon II